Gilead Sciences Inc (NASDAQ: GILD) says its drug conjugate Trodelvy disappointed in a late-stage cancer trial. Shares of the biotech firm opened about 10% down today. Trodelvy failed to meet primary endpoint Copy link to section Trodelvy did not meet the “primary endpoint of overall survival in previously treated metastatic non-small cell lung cancer”. EVOKE-01 – the aforementioned phase three trial evaluated the drug conjugate versus docetaxel, as per a press release on Monday. The news arrives only days b ...